- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
Patent holdings for IPC class C07D 209/20
Total number of patents in this class: 354
10-year publication summary
|
21
|
19
|
24
|
30
|
21
|
12
|
36
|
21
|
25
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Allergan, Inc. | 2347 |
9 |
| On Target Laboratories, LLC | 32 |
9 |
| Massachusetts Institute of Technology | 10062 |
6 |
| The Johns Hopkins University | 5675 |
6 |
| Apotex Technologies Inc. | 16 |
6 |
| Cybin UK Ltd | 39 |
6 |
| BELLUS Health Inc. | 13 |
5 |
| Heidelberg Pharma Research GmbH | 79 |
5 |
| Enveric Biosciences Canada Inc. | 62 |
5 |
| California Institute of Technology | 3977 |
4 |
| The Trustees of Columbia University in the City of New York | 3577 |
4 |
| Ajinomoto Co., Inc. | 2295 |
4 |
| Purdue Research Foundation | 3629 |
4 |
| Ramot at Tel-Aviv University Ltd. | 1477 |
4 |
| Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i. | 6 |
4 |
| The General Hospital Corporation | 4740 |
3 |
| Duke University | 3069 |
3 |
| Beyondspring Pharmaceuticals, Inc. | 83 |
3 |
| Givaudan SA | 1889 |
3 |
| Korea Research Institute of Bioscience and Biotechnology | 1058 |
3 |
| Other owners | 258 |